{"success":true,"data":{"pressRelease":{"id":"67761","rtpr_id":"nNFC5fFCJr","ticker":"JAGX","exchange":"NASDAQ","all_tickers":["JAGX","TRIP"],"title":"Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health","author":"Newsfile Corp","published_at":"2026-06-18T13:01:42.272Z","article_body":"* Whole leaf coca extract under evaluation is Magdalena's drug candidate for\npost GLP-1 weight loss management\nToronto, Ontario--(Newsfile Corp. - June 18, 2026) - Red Light Holland Corp.\n(CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (\"Red Light Holland\", \"Red Light\", or\nthe \"Company\") is an Ontario based organization advancing innovation and\nresearch within the legal psychedelic sector. Following its acquisition of\nFilament Health Corp. (\"Filament\"), the Company has expanded its\npharmaceutical grade manufacturing, regulatory, and clinical research\ncapabilities, supporting the advancement of naturally derived drug\ndevelopment. Through the Filament acquisition, the Company also holds\nFilament's interest in Magdalena Biosciences, Inc. (\"Magdalena\"), a US based\njoint venture formed by Filament and Jaguar Health, Inc. (NASDAQ: JAGX)\n(\"Jaguar\").\n\nThe Company is pleased to report that Magdalena has announced positive results\nof a preclinical study demonstrating that a novel extract derived from the\nleaves of the coca plant prevented weight gain in mice placed on a high fat\ndiet, without reducing food intake or increasing physical activity. The coca\nleaf extract under evaluation is Magdalena's prescription drug candidate for\npost-GLP-1 weight loss management, intended for development under the U.S.\nFood and Drug Administration's Botanical Guidance.\n\nIt is common for people to regain weight after stopping GLP-1 medications, as\nthese drugs help reduce appetite and increase feelings of fullness while they\nare being taken. When treatment is discontinued, those effects diminish, and\nthe body's mechanisms that regulate hunger and body weight may promote weight\ngain. Magdalena's thesis is that the coca leaf extract under evaluation may\nhave the potential to serve as a weight maintenance therapy following\ncessation of GLP-1 therapy, addressing a significant unmet need for safe, long\nterm weight management solutions.\n\nThe 20 day preclinical study was conducted in Alberta, Canada, in\ncollaboration with the Borgland Lab at the University of Calgary, where\nStephanie Borgland, PhD, served as Principal Investigator. The coca leaf used\nin the research and development program was provided to Magdalena by Empresa\nNacional de La Coca (ENACO), a Peruvian state company dedicated to the\ncommercialization of the coca leaf and its derivatives, under an\nInternationally Recognized Certificate of Compliance (IRCC) consistent with\nthe Nagoya Protocol requirements of Peru. Indigenous peoples and healers in\nthe Andean region have utilized coca for centuries to manage hunger and\nfatigue.\n\n\"This is an encouraging early result from Magdalena Biosciences and a clear\nexample of the broader value created through our acquisition of Filament,\"\nsaid Todd Shapiro, Chief Executive Officer and Director of both Red Light and\nFilament. \"Beyond Filament's leadership in standardized, naturally derived\npsilocybin, the acquisition gives Red Light an interest in a botanical drug\ndevelopment program addressing a large and growing unmet need in weight\nmanagement. We look forward to supporting Magdalena and our partners at Jaguar\nas this candidate advances under the FDA's Botanical Guidance.\"\n\nFilament is Red Light's wholly owned subsidiary and a partner, alongside\nJaguar, in the Magdalena Biosciences joint venture. The Company believes that\nthe development of standardized, naturally derived botanical medicines,\nadvanced under quality controlled and regulatory conscious frameworks, can\noffer new mechanisms of action while being potentially safer than chemically\nsynthesized small molecule drugs.\n\nAbout Red Light Holland\n\nRed Light is an Ontario based organization advancing a focused strategy within\nthe legal psychedelic sector, centered on consensual data collection and R&D\ninitiatives designed to expand naturally occurring drug development,\nunderstanding of psilocybin use and consumer experiences. In parallel, the\nCompany operates commercial activities across Europe and North America,\nincluding psilocybin truffle sales in the Netherlands' legal market and\nmushroom home grow kits offered through B2B and DTC channels, in compliance\nwith applicable laws.\n\nAbout Filament Health\n\nFilament Health is a clinical stage natural psychedelic drug development\ncompany. Filament believes that safe, standardized, naturally derived\npsychedelic medicines can improve the lives of many, and its mission is to see\nthem in the hands of everyone who needs them as soon as possible. Filament's\nplatform of proprietary intellectual property enables the discovery,\ndevelopment, and delivery of natural psychedelic medicines for clinical\ndevelopment. Filament is paving the way with the first ever natural\npsychedelic drug candidates.\n\nAbout Magdalena Biosciences\n\nMagdalena Biosciences, Inc. is a US based joint venture formed by Jaguar\nHealth, Inc. and Filament Health Corp. in 2023 to develop novel, natural\nprescription medicines derived from plants for weight gain prevention and\nmental health indications. Magdalena emerged from Jaguar's Entheogen\nTherapeutics Initiative (ETI). Boulder, Colorado based One Small Planet,\nfounded by Will Peterffy, has committed funding of US$1,000,000 to the\nventure.\n\nAbout Jaguar Health\n\nJaguar Health, Inc. (NASDAQ: JAGX) develops novel proprietary prescription\ndrugs sustainably derived from plants for people with complicated\ngastrointestinal disease states. Jaguar is Filament's partner in the Magdalena\nBiosciences joint venture.\n\nFor additional information on Red Light:\n\nTodd Shapiro\nChief Executive Officer & Director\nTel: 647-204-7129\nEmail: todd@redlight.co\nWebsite: www.RedLight.co\n\nCautionary Statement Regarding Forward-Looking Statements\n\nThis press release contains certain \"forward-looking information\" within the\nmeaning of applicable Canadian securities legislation. Such forward-looking\ninformation and forward-looking statements are not representative of\nhistorical facts or information or current conditions but instead represent\nonly the Company's beliefs regarding future events, plans or objectives, many\nof which, by their nature, are inherently uncertain and outside of the\nCompany's control. Often, but not always, forward-looking statements and\ninformation can be identified by the use of words such as \"plans\", \"expects\"\nor \"does not expect\", \"is expected\", \"estimates\", \"intends\", \"anticipates\" or\n\"does not anticipate\", or \"believes\", or variations of such words and phrases\nor state that certain actions, events or results \"may\", \"could\", \"would\",\n\"might\" or \"will\" be taken, occur or be achieved. Examples of such information\ninclude statements with respect to: the results of the preclinical study\nannounced by Magdalena and the interpretation of those results; the potential\nfor the coca leaf extract under evaluation to serve as a weight maintenance\ntherapy following cessation of GLP-1 therapy; the future development,\ncommercialization, and regulatory approval of the coca leaf extract drug\ncandidate, including under the FDA's Botanical Guidance; the Magdalena\nBiosciences joint venture and the Company's interest therein through Filament;\nthe recently completed acquisition of Filament Health and the expected\nintegration of Filament's infrastructure and intellectual property; and the\nexpected demand for standardized, naturally derived botanical medicines.\n\nForward-looking information in this news release is based on certain\nassumptions and expected future events, namely: that preclinical results may\ninform, but are not necessarily predictive of, the outcomes of any future\nclinical studies; the continued advancement of the coca leaf extract drug\ncandidate by Magdalena and its partners; the performance by the joint venture\npartners of their respective obligations; the continued supply of coca leaf\nand the ability to obtain and maintain any required regulatory permits and\napprovals, including import and export authorizations; the successful\nintegration of Filament Health following the completed acquisition; and\ngeneral business, market and economic conditions. Risks, uncertainties and\nother factors involved with forward-looking information could cause actual\nevents, results, performance, prospects and opportunities to differ materially\nfrom those expressed or implied by such forward-looking information, namely:\nthe risk that preclinical results do not translate into comparable clinical\noutcomes; the risk that the drug candidate does not advance or obtain\nregulatory approval; regulatory or enforcement developments affecting the\nlegal framework for coca and botanical drug research and supply; the risk that\nintegration of Filament Health is not completed as anticipated; delays in\nregulatory permitting, including import and export authorizations; and adverse\nchanges in the regulatory or political landscape affecting botanical drug\nresearch and access.\n\nAlthough the Company believes that the assumptions and factors used in\npreparing, and the expectations contained in, the forward-looking information\nand statements are reasonable, undue reliance should not be placed on such\ninformation and statements, and no assurance or guarantee can be given that\nsuch forward-looking information and statements will prove to be accurate, as\nactual results and future events could differ materially from those\nanticipated in such information and statements. The forward-looking\ninformation and forward-looking statements contained in this press release are\nmade as of the date of this press release, and the Company does not undertake\nto update any forward-looking information and/or forward-looking statements\nthat are contained or referenced herein, except in accordance with applicable\nsecurities laws.\n\nSource: Red Light Holland Corp.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/302047","article_body_html":"","raw_payload":{"data":{"id":"nNFC5fFCJr","title":"Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health","author":"Newsfile Corp","ticker":"JAGX","created":"2026-06-18T13:01:42.272Z","tickers":["JAGX","TRIP"],"exchange":"NASDAQ","article_body":"* Whole leaf coca extract under evaluation is Magdalena's drug candidate for\npost GLP-1 weight loss management\nToronto, Ontario--(Newsfile Corp. - June 18, 2026) - Red Light Holland Corp.\n(CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (\"Red Light Holland\", \"Red Light\", or\nthe \"Company\") is an Ontario based organization advancing innovation and\nresearch within the legal psychedelic sector. Following its acquisition of\nFilament Health Corp. (\"Filament\"), the Company has expanded its\npharmaceutical grade manufacturing, regulatory, and clinical research\ncapabilities, supporting the advancement of naturally derived drug\ndevelopment. Through the Filament acquisition, the Company also holds\nFilament's interest in Magdalena Biosciences, Inc. (\"Magdalena\"), a US based\njoint venture formed by Filament and Jaguar Health, Inc. (NASDAQ: JAGX)\n(\"Jaguar\").\n\nThe Company is pleased to report that Magdalena has announced positive results\nof a preclinical study demonstrating that a novel extract derived from the\nleaves of the coca plant prevented weight gain in mice placed on a high fat\ndiet, without reducing food intake or increasing physical activity. The coca\nleaf extract under evaluation is Magdalena's prescription drug candidate for\npost-GLP-1 weight loss management, intended for development under the U.S.\nFood and Drug Administration's Botanical Guidance.\n\nIt is common for people to regain weight after stopping GLP-1 medications, as\nthese drugs help reduce appetite and increase feelings of fullness while they\nare being taken. When treatment is discontinued, those effects diminish, and\nthe body's mechanisms that regulate hunger and body weight may promote weight\ngain. Magdalena's thesis is that the coca leaf extract under evaluation may\nhave the potential to serve as a weight maintenance therapy following\ncessation of GLP-1 therapy, addressing a significant unmet need for safe, long\nterm weight management solutions.\n\nThe 20 day preclinical study was conducted in Alberta, Canada, in\ncollaboration with the Borgland Lab at the University of Calgary, where\nStephanie Borgland, PhD, served as Principal Investigator. The coca leaf used\nin the research and development program was provided to Magdalena by Empresa\nNacional de La Coca (ENACO), a Peruvian state company dedicated to the\ncommercialization of the coca leaf and its derivatives, under an\nInternationally Recognized Certificate of Compliance (IRCC) consistent with\nthe Nagoya Protocol requirements of Peru. Indigenous peoples and healers in\nthe Andean region have utilized coca for centuries to manage hunger and\nfatigue.\n\n\"This is an encouraging early result from Magdalena Biosciences and a clear\nexample of the broader value created through our acquisition of Filament,\"\nsaid Todd Shapiro, Chief Executive Officer and Director of both Red Light and\nFilament. \"Beyond Filament's leadership in standardized, naturally derived\npsilocybin, the acquisition gives Red Light an interest in a botanical drug\ndevelopment program addressing a large and growing unmet need in weight\nmanagement. We look forward to supporting Magdalena and our partners at Jaguar\nas this candidate advances under the FDA's Botanical Guidance.\"\n\nFilament is Red Light's wholly owned subsidiary and a partner, alongside\nJaguar, in the Magdalena Biosciences joint venture. The Company believes that\nthe development of standardized, naturally derived botanical medicines,\nadvanced under quality controlled and regulatory conscious frameworks, can\noffer new mechanisms of action while being potentially safer than chemically\nsynthesized small molecule drugs.\n\nAbout Red Light Holland\n\nRed Light is an Ontario based organization advancing a focused strategy within\nthe legal psychedelic sector, centered on consensual data collection and R&D\ninitiatives designed to expand naturally occurring drug development,\nunderstanding of psilocybin use and consumer experiences. In parallel, the\nCompany operates commercial activities across Europe and North America,\nincluding psilocybin truffle sales in the Netherlands' legal market and\nmushroom home grow kits offered through B2B and DTC channels, in compliance\nwith applicable laws.\n\nAbout Filament Health\n\nFilament Health is a clinical stage natural psychedelic drug development\ncompany. Filament believes that safe, standardized, naturally derived\npsychedelic medicines can improve the lives of many, and its mission is to see\nthem in the hands of everyone who needs them as soon as possible. Filament's\nplatform of proprietary intellectual property enables the discovery,\ndevelopment, and delivery of natural psychedelic medicines for clinical\ndevelopment. Filament is paving the way with the first ever natural\npsychedelic drug candidates.\n\nAbout Magdalena Biosciences\n\nMagdalena Biosciences, Inc. is a US based joint venture formed by Jaguar\nHealth, Inc. and Filament Health Corp. in 2023 to develop novel, natural\nprescription medicines derived from plants for weight gain prevention and\nmental health indications. Magdalena emerged from Jaguar's Entheogen\nTherapeutics Initiative (ETI). Boulder, Colorado based One Small Planet,\nfounded by Will Peterffy, has committed funding of US$1,000,000 to the\nventure.\n\nAbout Jaguar Health\n\nJaguar Health, Inc. (NASDAQ: JAGX) develops novel proprietary prescription\ndrugs sustainably derived from plants for people with complicated\ngastrointestinal disease states. Jaguar is Filament's partner in the Magdalena\nBiosciences joint venture.\n\nFor additional information on Red Light:\n\nTodd Shapiro\nChief Executive Officer & Director\nTel: 647-204-7129\nEmail: todd@redlight.co\nWebsite: www.RedLight.co\n\nCautionary Statement Regarding Forward-Looking Statements\n\nThis press release contains certain \"forward-looking information\" within the\nmeaning of applicable Canadian securities legislation. Such forward-looking\ninformation and forward-looking statements are not representative of\nhistorical facts or information or current conditions but instead represent\nonly the Company's beliefs regarding future events, plans or objectives, many\nof which, by their nature, are inherently uncertain and outside of the\nCompany's control. Often, but not always, forward-looking statements and\ninformation can be identified by the use of words such as \"plans\", \"expects\"\nor \"does not expect\", \"is expected\", \"estimates\", \"intends\", \"anticipates\" or\n\"does not anticipate\", or \"believes\", or variations of such words and phrases\nor state that certain actions, events or results \"may\", \"could\", \"would\",\n\"might\" or \"will\" be taken, occur or be achieved. Examples of such information\ninclude statements with respect to: the results of the preclinical study\nannounced by Magdalena and the interpretation of those results; the potential\nfor the coca leaf extract under evaluation to serve as a weight maintenance\ntherapy following cessation of GLP-1 therapy; the future development,\ncommercialization, and regulatory approval of the coca leaf extract drug\ncandidate, including under the FDA's Botanical Guidance; the Magdalena\nBiosciences joint venture and the Company's interest therein through Filament;\nthe recently completed acquisition of Filament Health and the expected\nintegration of Filament's infrastructure and intellectual property; and the\nexpected demand for standardized, naturally derived botanical medicines.\n\nForward-looking information in this news release is based on certain\nassumptions and expected future events, namely: that preclinical results may\ninform, but are not necessarily predictive of, the outcomes of any future\nclinical studies; the continued advancement of the coca leaf extract drug\ncandidate by Magdalena and its partners; the performance by the joint venture\npartners of their respective obligations; the continued supply of coca leaf\nand the ability to obtain and maintain any required regulatory permits and\napprovals, including import and export authorizations; the successful\nintegration of Filament Health following the completed acquisition; and\ngeneral business, market and economic conditions. Risks, uncertainties and\nother factors involved with forward-looking information could cause actual\nevents, results, performance, prospects and opportunities to differ materially\nfrom those expressed or implied by such forward-looking information, namely:\nthe risk that preclinical results do not translate into comparable clinical\noutcomes; the risk that the drug candidate does not advance or obtain\nregulatory approval; regulatory or enforcement developments affecting the\nlegal framework for coca and botanical drug research and supply; the risk that\nintegration of Filament Health is not completed as anticipated; delays in\nregulatory permitting, including import and export authorizations; and adverse\nchanges in the regulatory or political landscape affecting botanical drug\nresearch and access.\n\nAlthough the Company believes that the assumptions and factors used in\npreparing, and the expectations contained in, the forward-looking information\nand statements are reasonable, undue reliance should not be placed on such\ninformation and statements, and no assurance or guarantee can be given that\nsuch forward-looking information and statements will prove to be accurate, as\nactual results and future events could differ materially from those\nanticipated in such information and statements. The forward-looking\ninformation and forward-looking statements contained in this press release are\nmade as of the date of this press release, and the Company does not undertake\nto update any forward-looking information and/or forward-looking statements\nthat are contained or referenced herein, except in accordance with applicable\nsecurities laws.\n\nSource: Red Light Holland Corp.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/302047"},"type":"article","timestamp":"2026-06-18T13:01:42.332889569Z","server_sent_at_ms":1781787702332},"received_at":"2026-06-18T13:01:42.408Z","source_url":"https://www.newsfilecorp.com/release/302047"},"analysis":{"id":"57178","press_release_id":"67761","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["preclinical data in mice is early-stage and high-risk","regulatory pathway for botanical drugs is complex"],"eventType":"clinical_trial","narrative":"Magdalena Biosciences, a joint venture between Filament Health and Jaguar Health, reported positive preclinical data showing a coca leaf extract prevented weight gain in mice without reducing food intake.\n\nThe extract is being developed as a prescription drug for post-GLP-1 weight management under the FDA's Botanical Guidance, targeting the significant unmet need of weight regain after cessation of GLP-1 therapies.\n\nThe 20-day study was conducted in collaboration with the University of Calgary's Borgland Lab, and One Small Planet has committed US$1,000,000 in funding to the venture.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"JV partner reports positive mouse data for coca extract targeting GLP-1 rebound weight gain."},"keyFigures":{"customDimensions":{"study_duration_days":20,"funding_commitment_usd":1000000}},"quotedText":"This is an encouraging early result from Magdalena Biosciences and a clear example of the broader value created through our acquisition of Filament","namedEntities":{"people":[{"name":"Todd Shapiro","role":"CEO of Red Light Holland and Filament Health"},{"name":"Stephanie Borgland","role":"Principal Investigator"},{"name":"Will Peterffy","role":"Founder of One Small Planet"}],"products":["coca leaf extract","psilocybin"],"companies":[{"name":"Red Light Holland Corp.","ticker":"TRIP","relationship":"partner / issuer"},{"name":"Filament Health Corp.","relationship":"partner / subsidiary"},{"name":"Magdalena Biosciences, Inc.","relationship":"joint venture"},{"name":"Jaguar Health, Inc.","ticker":"JAGX","relationship":"partner"},{"name":"One Small Planet","relationship":"investor"},{"name":"Empresa Nacional de La Coca (ENACO)","relationship":"supplier"},{"name":"Borgland Lab at the University of Calgary","relationship":"research partner"}],"dollarAmounts":[{"amount":"US$1,000,000","context":"funding commitment from One Small Planet"}]},"materialImpact":{"score":2,"reasoning":"Positive preclinical results in mice for a joint venture asset. While the data supports the post-GLP-1 weight management thesis, early-stage animal studies carry high uncertainty and are not yet binary clinical events."},"tickerRelevance":{"others":[{"ticker":"TRIP","relevance":"partner / issuer"},{"ticker":"4YX","relevance":"partner / issuer"},{"ticker":"TRUFF","relevance":"partner / issuer"}],"primary":"JAGX"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro_small_cap","topicTrend":"GLP-1","eventGravity":"preclinical_mice_data","sectorWeight":"biotech"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Magdalena Biosciences, a joint venture between Filament Health and Jaguar Health, reported positive preclinical data showing a coca leaf extract prevented weight gain in mice without reducing food intake.\n\nThe extract is being developed as a prescription drug for post-GLP-1 weight management under the FDA's Botanical Guidance, targeting the significant unmet need of weight regain after cessation of GLP-1 therapies.\n\nThe 20-day study was conducted in collaboration with the University of Calgary's Borgland Lab, and One Small Planet has committed US$1,000,000 in funding to the venture.","key_figures":{"customDimensions":{"study_duration_days":20,"funding_commitment_usd":1000000}},"named_entities":{"people":[{"name":"Todd Shapiro","role":"CEO of Red Light Holland and Filament Health"},{"name":"Stephanie Borgland","role":"Principal Investigator"},{"name":"Will Peterffy","role":"Founder of One Small Planet"}],"products":["coca leaf extract","psilocybin"],"companies":[{"name":"Red Light Holland Corp.","ticker":"TRIP","relationship":"partner / issuer"},{"name":"Filament Health Corp.","relationship":"partner / subsidiary"},{"name":"Magdalena Biosciences, Inc.","relationship":"joint venture"},{"name":"Jaguar Health, Inc.","ticker":"JAGX","relationship":"partner"},{"name":"One Small Planet","relationship":"investor"},{"name":"Empresa Nacional de La Coca (ENACO)","relationship":"supplier"},{"name":"Borgland Lab at the University of Calgary","relationship":"research partner"}],"dollarAmounts":[{"amount":"US$1,000,000","context":"funding commitment from One Small Planet"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-18T13:44:42.926Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"micro_small_cap","topicTrend":"GLP-1","eventGravity":"preclinical_mice_data","sectorWeight":"biotech"}},"durationMs":121961,"modelName":"george-droid-qwen-72b"}}